News and Blog
Welcome to your information hub to keep up to date with our latest news, product launches, industry insights, case studies and much more.
View all blogs:
Croda Pharma launches a new bioprocessing solution for shear stress in mammalian cell culture
Croda Pharma has announced the launch of Super Refined™ Poloxamer 188, an innovative bioprocessing solution developed to meet the increasing demands of biopharmaceutical development.
Announcing Avanti Research - a Croda brand
Avanti Polar Lipids, a global leader in lipids, has announced its renewed offering for researchers and its transformation to Avanti Research.
EXCLUSIVE WHITEPAPER: Next-generation Triton™ X-100 replacements for pharmaceutical bioprocessing
Triton™ X-100 (tert-octyl phenyl ethoxylate) is used extensively in the manufacture of biologics, plasma-derived products and cell and gene therapies (CGTs). This non-ionic detergent is used because...
.png?w=768&la=es-MX&focalpointcrop=1&xratio=0&yratio=0&hash=B301C96CCD8120143037862319E11640)
Veterinary vaccines - solutions for an ongoing challenge...
Growth in the veterinary pharmaceutical industry continues to be driven by increasing pet ownership globally and the rising demand for veterinary vaccines to prevent the risk of zoonotic diseases in...
.png?w=768&la=es-MX&focalpointcrop=1&xratio=0&yratio=0&hash=8D4A4716F7413779B7F202A086E07C9F)
QbD Formulation Development
Formulation development is a pivotal stage in the life cycle of a therapeutic drug product, it can be the make or break of it. The goal of formulation development is to convert active substance (drug...
Croda joins CGT Catapult consortium to improve AAV formulation
The Cell and Gene Therapy Catapult (CGT Catapult) has established a cross-industry consortium to improve the understanding and process optimisation of adeno-associated virus (AAV) formulation.
Partnership agreement between Croda and AAHI to drive innovation in vaccine development
19 March 2024: Croda International Plc (Croda) and The Access to Advanced Health Institute (AAHI) are pleased to announce today the signing of a partnership agreement around innovation and development...
Croda Foundation announces it has sustainably improved the lives of 22.8 million people – exceeding its 2030 target.
Croda Foundation announces it has sustainably improved the lives of 22.8 million people –exceeding its 2030 target.
Specializing in specific enhancement technologies
Croda Pharma specializes in four technologies aimed at improving bioavailability and solubility. Find out more!
Concerns about Triton™ X-100 have been an ongoing discussion across multiple regulatory authorities around the world
Triton™ X-100, a non-ionic surfactant with a hydrophilic polyethylene oxide chain and a hydrophobic aromatic group1, has found widespread use in the biopharmaceutical industry with applications...
“Close the Care Gap” – World Cancer Day 2024
We are proud to continue supporting the development of cancer treatments, and on this World Cancer Day, recognise the importance of innovation and science to cure and treat those diagnosed. Together,...
Spotlight on Kritika Bajaj
Highlighting the scientists and teams who are involved in our latest product launch, Virodex™, replacements for Triton™ X-100, we sat down with Kritika Bajaj and asked her about her involvement around...
Croda’s response to Sustainable Markets Initiative for supplier sustainability targets
The recent open letter from the Sustainable Markets Initiative Health Systems Task Force called for Healthcare supply chains to become greener, more efficient and circular and set out a series of...
Sustainability for vaccines: Decarbonisation of one of our key sites
Sustainability is often defined as meeting the needs of those alive today without compromising the ability of future generations to meet their needs. It is a long-term goal that covers three pillars:...
A powerful match - celebrating three years of Croda Pharma and Avanti
Today marks three years since we acquired Avanti Polar Lipids. During the COVID-19 pandemic, it became clear that the combination of Avanti's lipid expertise and our manufacturing scale-up capability...
Introducing new bioprocessing solutions to replace banned materials
We have introduced a critical range of new bioprocessing detergents optimised for viral inactivation and cell lysis. The company’s new product range, Virodex™, offers an answer to the key market need...
Cholesterol: enhancing stability and efficacy in lipid-based drug delivery
Cholesterol, a key component in lipid-based drug delivery systems, provides structural support and stability, enhances the efficiency of intracellular delivery and gene transfection.
Acquisition of Solus Biotech expands specialised Pharma business in Asia
05 July 2023: Croda International Plc (‘Croda’) announced that it has acquired Solus Biotech, a global leader in premium, biotechnology-derived materials, from Solus Advanced Materials
Acquisition of Solus Biotech strengthens Croda Pharma
On 04 July Croda successfully completed the acquisition of Solus Biotech, an innovative biotechnology company with over three decades of industry experience.
Croda opens new Global Technical Centre at Genome Valley, Hyderabad, India
PRESS RELEASE – On June 21, 2023, Croda International Plc opened its new Global Technical Centre at Genome Valley, Hyderabad, India.
Croda breaks ground on new manufacturing facility for pharmaceutical excipients in Lamar, Pennsylvania
31st May 2023: Croda, Inc., the company that uses smart science to create high-performance ingredients and solutions that improve lives, broke ground on 9 May 2023, its newest manufacturing facility...
From Triton X-100 to Virodex: exploring our innovative solution to the Triton X-100 ban
For those who have previously relied on Triton™ X-100 as a surfactant or detergent in their manufacturing processes there is now an urgent need to find a suitable replacement. Explore Croda's...
Croda announces two new partnerships to drive sustainable delivery systems for the pharmaceutical industry
19 May 2023: Croda International Plc (Croda) today announced that it has signed two new partnership agreements that will help the pharmaceutical industry move towards a more sustainable supply chain...
The future of mRNA delivery: Advancements in engineering lipid nanoparticles for enhanced intracellular delivery through inhalation
Messenger RNA (mRNA) has played a crucial role in recent vaccine developments and is at the forefront of much current medical research. Traditionally. the delivery of mRNA systemically via lipid...
Oral Drug Delivery
The oral route of administration presents a convenient, cost-effective, and non-invasive method for delivering drugs. However, with the increasing complexity of APIs, the delivery of these drugs also...
Revolutionizing gene editing: How RGD peptide-based lipids could be the key to effective mRNA delivery
Gene editing has emerged as a promising strategy for treating a wide range of genetic disorders. However, the efficacy of gene therapy is limited by the challenge of delivering therapeutic agents to...
Precision medicine revolution: The potential of DSPE-RGD in targeted drug delivery
In recent years, researchers and clinicians have been exploring new ways to deliver drugs directly to the cells and tissues that need them, while minimizing side effects on healthy cells. One of the...
Promising new results for metastatic prostate cancer vaccine
A new study1 published in Frontiers in Immunology reports promising vaccine results for patients with hormone-sensitive prostate cancer. The researchers demonstrated that a vaccine formulation...
Lipids in Small-Molecule Pro-Drugs
Lipids are used in therapeutics in many ways. Some lipids have even been used as small-molecule drugs to treat specific diseases, and are also being used to improve undesirable characteristics of...
Our veterinary health offering
We are the global partner for high quality excipients, adjuvant systems and formulation support for the animal health industry, and we are continuously innovating to provide break-through solutions...
Croda Pharma welcomes Dave Cherry
We warmly welcome Dave Cherry as our new Global Managing Director. David brings with him past experiences from his work with the wider Life Sciences Leadership Team and healthcare markets, which is...
Introducing our Adjuvant Systems Platform
Introducing our Adjuvant Systems platform. Leveraging a history of developing adjuvants since 1939, our scientists deliver high performance adjuvants to meet your vaccine needs today.
Introducing our Nucleic Acid Delivery platform
This post introduces our Nucleic Acid Delivery platform, a technology area that was strengthened through our acquisition of Avanti Polar Lipids in 2020.
Croda Pharma: The future of novel excipients
The importance of excipients and their specialised role in formulation development has been recognised in recent years, whether that be for targeting delivery of the drug, aesthetics of the final...
Expert Q&A - Dr Stephen Rumbelow:
Formulating a drug for parenteral delivery comes with its fair set of challenges. Aside from a high level of sensitivity to external factors like light and heat exposure, these large and complex drugs...
Lipid technology for delivery of gene editing therapies
Gene-editing is one of the most eagerly anticipated biopharma developments in recent history. However, one of the biggest hurdles to the development of successful gene-editing therapeutics is...
Excipient sustainability - A user and a supplier perspective
To achieve their sustainability ambitions excipient users need to access excipients produced with lower embedded GHG emissions, little or no waste produced and with minimal impact on water quality and...
Things to consider when choosing a cationic lipid for your formulation
Lipid-based therapeutic delivery systems have been evolving for many years. From delivering naked mRNA, to using liposomes, and now lipid nanoparticles,
Innovative lipids for your nucleic acid delivery research
Lipid-based therapeutic delivery systems have been evolving for many years. From delivering naked mRNA, to using liposomes, and now lipid nanoparticles,
Introducing our Small Molecule Delivery platform
Our offering for Small Molecule Delivery focuses on tackling your formulation challenges and enhancing drug delivery through our high purity Super Refined™ excipients. Over the years, enhancing...
Lipid Leaders: Dennis Christensen
In this Lipid Leaders interview, we get insight from Croda Pharma's own Global Head of R&D - Adjuvant Systems, Dennis Christensen, PhD. Keep reading to learn more about adjuvants and the role they...
Proprietary purification process extends formulation shelf life
Formulating generic drugs of equivalent stability, safety, bioequivalence, and dosage form as originator drugs can be a great challenge. James Humphrey, Research and Technology Specialist explores how...
Our Healthcare division becomes Croda Pharma
Croda International Plc, the company that uses smart science to create high performance ingredients and solutions that improve lives, has today announced that its Health Care division will now become...
Croda Pharma wins prestigious “Best Supplier for COVID-19 Vaccine Development 2022” Award
Croda, the company that uses smart science to improve lives, announces that it has been awarded winner a prestigious award for its work in supporting vaccine development. The company has been awarded...
Exclusive license for Croda to commercialise SSI’s CAF® vaccine adjuvants
Croda International Plc, which uses smart science to improve lives, announces today that it has entered a strategic collaboration with Statens Serum Institut (“SSI”), the leading Danish Governmental...
Croda expands its high purity pharmaceutical excipients manufacturing capability
This investment confirms Croda’s commitment to building its Life Sciences business and developing innovative pharmaceutical excipients, reinforcing Croda’s Purpose to use Smart science to improve...
Strengthening Life Sciences with the acquisition of Avanti Polar Lipids
13 August 2020: A leader in drug delivery systems for next generation pharmaceuticals, the acquisition more than doubles Croda’s research and development (R&D) capability in drug delivery.
Lets connect...
Register to the mailing list to unlock:
- First access to new products, new data and exclusive literature
- Whitepapers and thought provoking content
- Special offers on conference and exhibition passes when available
- Invitations to invite only Croda Pharma events.